

Law and Biotechnology

*Carolina Academic Press
Law Casebook Series
Advisory Board*



Gary J. Simson, Chairman
Dean, Case Western Reserve University School of Law

Raj Bhala
University of Kansas School of Law

John C. Coffee, Jr.
Columbia University Law School

Randall Coyne
University of Oklahoma College of Law

John S. Dzienkowski
University of Texas School of Law

Paul Finkelman
Albany Law School

Robert M. Jarvis
*Shepard Broad Law Center
Nova Southeastern University*

Vincent R. Johnson
St. Mary's University School of Law

Michael A. Olivas
University of Houston Law Center

Kenneth Port
William Mitchell College of Law

Michael P. Scharf
Case Western Reserve University School of Law

Peter M. Shane
*Michael E. Moritz College of Law
The Ohio State University*

Emily L. Sherwin
Cornell Law School

John F. Sutton, Jr.
Emeritus, University of Texas School of Law

David B. Wexler
*John E. Rogers College of Law
University of Arizona*

Law and Biotechnology

Cases and Materials

Victoria Sutton

ROBERT H. BEAN PROFESSOR OF LAW
TEXAS TECH UNIVERSITY
SCHOOL OF LAW

CAROLINA ACADEMIC PRESS

Durham, North Carolina

Copyright © 2007
Victoria Sutton
All Rights Reserved

ISBN 10: 0-89089-191-5, ISBN 13: 978-0-89089-191-9
LCCN 2006924478

CAROLINA ACADEMIC PRESS
700 Kent Street
Durham, North Carolina 27701
Telephone (919) 489-7486
Fax (919) 493-5668
www.cap-press.com

Printed in the United States of America

Chapter One	Introduction	3
1.1	The Relationship between Law and Biotechnology	3
1.1.1	Defining Biotechnology	4
1.1.1.1	Monoclonal Antibody Technology	4
1.1.1.2	Cell Culture Technology	5
1.1.1.3	Genetic Engineering Technology	5
1.1.1.4	Biosensor Technology	6
1.1.1.5	Antisense Technology	6
1.1.1.6	DNA Chip Technology	6
1.1.1.7	Tissue Engineering	7
1.1.1.8	Bioprocessing Technology	7
1.1.1.9	Bioinformatics	8
1.1.2	Defining Bioengineering	9
1.1.3	Defining Genomics	9
1.1.4	Defining Proteomics	10
1.1.5	Defining Nanobiotechnology	10
1.2	The History of Biotechnology and Law in Eurasia and the Americas	11
1.3	Introduction to the Scientific Method and Biotechnology	18
1.4	Biotechnology—What New Questions Have Been Raised?	20
	<i>Diamond v. Chakrabarty</i>	20
	Notes	26
	<i>Pioneer Hi-Bred International, Inc. v. J.E.M. Ag Supply</i>	27
	Notes	29

V

2.1.3	Food and Drug Administration and the Environmental Protection Agency: Genetically Engineered Foods	42
2.1.3.1	History of Law and Food Regulation	42
2.1.3.2	The Controversy over Genetically Engineered Foods	47
	<i>Stauber v. Shalala and Kessler</i>	48
	<i>Alliance for Bio-Integrity v. Shalala</i>	59
	Notes	66
2.1.3.3	The Regulation of Genetically Engineered Foods	67
2.1.3.4	Constitutional First Amendment Limitations in State Labeling Regulations	70
	<i>International Dairy Foods Association v. Amestoy, Attorney General of the State of Vermont</i>	70
	Notes	80
2.1.4	U.S. Environmental Protection Agency and Department of Agriculture: Genetically Engineered Plants	82
	<i>Foundation on Economic Trends v. Thomas</i>	82
	<i>Foundation on Economic Trends v. Lyng</i>	86
	Notes	89
2.1.5	U.S. Environmental Protection Agency, National Institutes of Health: Genetically Modified Organisms	90
	<i>Foundation on Economic Trends v. Heckler</i>	90
	<i>Foundation on Economic Trends v. Block</i>	99
	<i>Foundation on Economic Trends v. Bowen</i>	101
	Notes	106
2.1.6	U.S. Department of Agriculture and BioPharming	106
	<i>Center for Food Safety v. Veneman</i>	110
	<i>Center for Food Safety v. Johanns</i>	111
2.2	Legislative Branch	121
2.2.1	Legislation and Problems with Biotechnology	121
	Notes	129
2.2.2	Genetic Preservation	129
2.2.3	Cloning Prohibition	130
2.3	State Governments and Biotechnology Regulation	131
2.3.1	Biotechnology and State Support	131
2.3.2	State Codes	132
Chapter Three	Private Sector Profits and Biotechnology	137
3.1	Introduction	137
3.2	Biotechnology Issues in Fraud	138
3.2.1	Securities Fraud	138
	<i>In Re Ribozyme Pharmaceuticals, Inc. Securities Litigation</i>	138
	Notes	143
3.2.2	Contract Fraud	144
	<i>Rhone-Poulenc Agro S.A. v. Monsanto Company and Dekalb Genetics Corp.</i>	144
3.3	Intellectual Property Protection Issues	149
3.3.1	Trade Secrets as an Approach to Protecting Corporate Knowledge	149
	<i>Microbix Biosystems, Inc. v. Biowhittaker, Inc.</i>	150

	<i>North Carolina Farm Partnership v. Pig Improvement Company, Inc.</i>	152
3.3.2	Patenting as an Approach to Protecting Corporate Knowledge in Corporate Competitive Research	153
	<i>Scripps Clinic and Research Foundation v. Genentech, Inc.</i>	154
3.4	Bioprospecting—Private Sector Agreements with the Government	156
	<i>Edmonds Institute v. Babbitt, Secretary of Interior</i>	156
3.5	Patents in Biotechnology	164
3.5.1	Biotechnology Patents Applications Requirements	167
3.5.1.1	The Utility Requirement	168
3.5.1.2	The Written Description Requirement. 35 U.S.C. § 112	168
3.5.1.3	The Enabling Requirement. 35 U.S.C. § 112	169
	<i>In Re Thomas Deuel</i>	169
	<i>Amgen, Inc. v. Hoechst</i>	173
3.5.2	Unique Problems in Patenting Biotechnology	178
	<i>Monsanto Canada, Inc. v. Schmeiser</i>	178
	<i>Schmeiser v. Monsanto Canada Inc.</i>	191
3.6	New Professions and Legal Issues	208
3.6.1	Bioengineers	208
3.6.2	Genetic Counselors	209
	Notes	211
Chapter Four	Human Health, Medical Care, Medical Information	
	Disclosure in Biotechnology	215
4.1	Disclosure of Medical Information and Privacy	215
4.1.1	Right to Privacy	215
4.1.2	Limited Right to Privacy	216
4.1.2.1	Limited Right to Privacy in the Military	216
	<i>Mayfield v. Dalton</i>	216
4.1.2.2	Adoption Right to Know	218
	<i>In the Matter of Sandra L.G. v. Bouchev</i>	218
4.1.3	Use of Genetic Information	220
4.2	Informed Consent, High Risk Treatments and Research	224
	Notes	229
4.3	Insurance and Predisposition to Disease	229
	<i>Katskee v. Blue Cross/Blue Shield of Nebraska</i>	229
	Notes	230
Chapter Five	International Law and Biotechnology	231
5.1	International Environment and Biotechnology Issues	231
5.2	Introduction to Biodiversity and the Convention on Biological Diversity (CBD)	231
5.2.1	The Convention on Biological Diversity	232
5.2.1.1	History and Background of the Convention on Biological Diversity (CBD)	232
5.2.1.2	Structure of the Convention on Biological Diversity	233
	5.2.1.2.1 Article 8(j)	235
	5.2.1.2.2 Article 15. Access to Genetic Resources	236
5.3	Bioprospecting and International Biopiracy	237

5.3.1	International Approaches to Bioprospecting	238
5.3.1.1	Convention on Biological Diversity	238
5.3.1.2	FAO International Treaty on Plant Genetic Resources for Food and Agriculture	238
5.3.1.3	WTO Agreement on Trade-Related Aspects of Intellectual Property Rights	238
5.3.1.4	International Convention for the Protection of New Varieties of Plants	239
5.3.1.5	Convention on International Trade in Endangered Species of Wild Fauna and Flora	240
5.3.1.6	The Antarctic Treaty	240
5.3.1.7	Universal Declaration of Human Rights	240
5.3.1.8	International Covenant on Economic, Social and Cultural Rights	240
5.3.2	Regional Agreements	240
5.4	International Codes of Conduct for Bioprospecting	241
5.4.1	The Micro-Organisms Sustainable Use and Access Regulation International Code of Conduct (MOSAICC)	241
5.4.2	Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising Out of Their Utilization	244
5.5	International Intellectual Property and Biotechnology	246
5.5.1	Patent Protection in the United States	246
5.5.2	Patent Protection in Other Countries	246
5.5.3	International Patenting	247
5.6	International Trade and Biotechnology	247
5.6.1	Exporting Biotechnologies	247
5.6.2	The Cartagena Biosafety Protocol	247
5.7	International Security	248
5.8	International Human Rights and Biotechnology	248
5.8.1	United Nations Treaty on Indigenous Peoples and Human Rights	248
5.9	Human DNA	249
Chapter Six	Bioethics, Religion and Biotechnology	253
6.1	Law, Biotechnology and Religion: Humans' Relationship with Biotechnology and Religion	253
6.1.1	Free Exercise Clause Challenge to Biotechnology	253
	<i>Alliance for Bio-Integrity v. Shalala</i>	253
	Notes	256
6.1.2	Religious Views on Biotechnology	256
6.1.2.1	Stem Cell Research and Religion	256
6.1.2.2	Cloning and Religion	258
6.2	Ethics and Biotechnology	260
6.2.1	Public Sector Considers Ethics and Biotechnology	260
6.2.2	The Private Sector Considers Ethics and Biotechnology	262
6.3	Family Relations: Legal v. Biological	262
	<i>Stitham v. Henderson</i>	262
6.4	Reproductive Technologies	265

<i>Margaret S. v. Edwards</i>	265
<i>Lifchez v. Hartigan</i>	266
Notes	269
6.4.1 Post Mortem Sperm Collection	270
6.4.2 Ectogenesis	272
6.5 Eugenics	273
6.6 Stem Cell Research	274
6.6.1 The Controversy with Stem Cell Research	274
6.6.2 What Are These Embryonic Stem Cells?	276
6.6.3 Sources of Embryonic Stem Cells	276
6.6.4 State Regulation of Stem Cell Research	276
Notes	277
6.7 Cloning	277
6.8 The Ethics of Contamination of Indigenous Crops with Genetically Modified Crops	278
Chapter Seven Criminal Law and Biotechnology	283
7.1 Existing Federal Crimes Applicable to New Problems in Biotechnology	283
7.1.1 Mail Fraud	283
<i>United States v. Greene</i>	283
7.1.2 The Great Train Robbery in Biotechnology	284
7.2 The Use of DNA in Criminal Law	290
<i>Spencer v. Murray</i>	290
7.3 New Federal Statutes for New Problems in Biotechnology	292
<i>United States v. Wise</i>	293
<i>United States v. Slaughter</i>	296
Notes	300
7.4 Biotechnology and the Changing Concept of “Expectation of Privacy”	300
<i>Illinois v. Wealer</i>	301
<i>People v. King</i>	303
Notes	306
7.5 Human Behavioral Genetics and Criminal Predisposition	306
<i>Buck v. Bell</i>	310
<i>New York v. Weinstein</i>	311
Notes	314
7.6 Criminal Law Attorneys and Obligation to Understand Science	314
7.6.1 The Genetics Defense	314
7.6.2 Ineffective Assistance of Counsel	315
<i>Mobley v. Head</i>	315
<i>Ohio v. Lane</i>	318
7.7 Biopiracy	319
Chapter Eight Scientific Evidence and Biotechnology	321
8.1 Introduction	321
8.2 The Legal Foundation of Scientific Evidence	321
<i>Frye v. United States</i>	322
<i>Daubert v. Merrell Dow Pharmaceuticals, Inc.</i>	324
<i>General Electric Company v. Joiner</i>	332

	<i>Kumho Tire Company v. Carmichael</i>	338
8.3	Mitochondrial DNA	346
	<i>United States v. Beverly</i>	347
8.4	Historical Forensics and the Use of DNA Evidence	353
8.4.1	Thomas Jefferson and Sally Hemings	353
8.4.2	Abraham Lincoln and Marfan Syndrome?	353
	Notes	354
Chapter Nine	Biotechnology and Property Law	355
9.1	Introduction	355
9.2	Ownership Problems	355
	<i>Moore v. Regents of University of California</i>	355
	<i>Miles, Inc. v. Scripps Clinic and Research Foundation</i>	362
9.3	Special Property Protection Problems of Biotechnology:	
	Patent Ownership Problems	368
	<i>In Re Thomas Deuel</i>	369
	<i>Animal Legal Defense Fund v. Quigg</i>	375
9.4	Ownership of Human Organs	378
9.5	Ownership of Human Fertilized Eggs	389
	<i>Kass v. Kass</i>	389
9.6	Umbilical Cord Blood Banks	391
	Notes	393
Chapter Ten	Biotechnology and Tort Law	395
10.1	Intentional Torts	395
	<i>Moore v. Regents of University of California</i>	396
	<i>In Re Starlink Corn Products Liability Litigation</i>	402
10.2	Unintentional Torts	409
10.2.1	Wrongful Birth/Wrongful Life: Medical Malpractice	410
	<i>Shroeder v. Perkel</i>	410
	<i>Reed v. Campagnolo</i>	415
10.2.2	Products Liability	427
	<i>In Re Starlink Corn Products Liability Litigation</i>	431
10.2.3	Strict Liability Legislation	435
Chapter Eleven	The Future of Biotechnology and Law	437
Appendix 1	Primer on Cell Biology	447
Appendix 2	Primer on Molecular Biology	451
Appendix 3	Primer on DNA	455
Appendix 4	Glossary	461
Index		473

Table of Cases

- Alliance for Bio-Integrity v. Shalala, 59, 66–67, 253
- Amgen v. Hoechst, vii, 169, 173–178, 198
- Amgen, Inc. v. Hoechst, 173
- Animal Legal Defense Fund v. Quigg, 375
- Attorney General of the State of Vermont, 70
- Buck v. Bell, 310–311
- California v. Greenwood, 300
- Center for Food Safety v. Johanns, 111
- Center for Food Safety v. Veneman, 110
- Daubert v. Merrell Dow Pharmaceuticals, Inc., 323–324, 332, 334–338, 340–346, 349
- Diamond v. Chakrabarty, 20, 27, 29, 163–164, 169, 361, 373, 376–378
- Edmonds Institute v. Babbitt, Secretary of Interior, 156
- Foundation on Economic Trends v. Block, 99
- Foundation on Economic Trends v. Bowen, 101
- Foundation on Economic Trends v. Heckler, 90, 96
- Foundation on Economic Trends v. Lyng, 86–88
- Foundation on Economic Trends v. Thomas, 82, 84
- Frye v. United States, 321–322, 324, 327, 330
- General Electric Company v. Joiner, 26, 332
- Illinois v. Wealer, 301
- In Re Deuel, 369
- In Re Ribozyme Pharmaceuticals, Inc. Securities Litigation, 138
- In Re Starlink Corn Products Liability Litigation, 402, 431
- In Re Thomas Deuel, 169, 369
- In the Matter of Sandra L.G. v. Bouchey, 218
- International Dairy Foods Association v. Amestoy, Attorney General of the State of Vermont, 70, 129
- Kass v. Kass, 389
- Katskee v. Blue Cross/Blue Shield of Nebraska, 229, 300–301
- Katz v. United States, 300
- Kumho Tire Company v. Carmichael, 338
- Lifchez v. Hartigan, 266
- Margaret S. v. Edwards, 265, 267
- Mayfield v. Dalton, 216
- Microbix Biosystems, Inc. v. Biowhittaker, Inc., 150, 152
- Miles, Inc. v. Scripps Clinic and Research Foundation, 362
- Mobley v. Head, 315
- Monsanto Canada Inc. v. Schmeiser, 178–179, 191–192
- Moore v. Regents of University of California, 355–361, 364–366, 388, 396–401, 426
- New York v. Weinstein, 311
- North Carolina Farm Partnership v. Pig Improvement Company, Inc., 152
- Ohio v. Lane, 318
- Olmstead v. United States, 300
- People v. King, 302–303
- Pioneer Hi-Bred International, Inc. v. J.E.M. Ag Supply, 27, 185
- Reed v. Campagnolo, 415–416, 418
- Rhone-Poulenc Agro S.A. v. Monsanto Company and Dekalb Genetics Corp., 144
- Schmeiser v. Monsanto Canada Inc., 191
- Scripps Clinic and Research Foundation v. Genentech, Inc., 154
- Shroeder v. Perkel, 410
- Spencer v. Murray, 290
- Stauber v. Shalala and Kessler, 48
- Stitham v. Henderson, 262
- United States v. Beverly, 347
- United States v. Dina Abdelhaq, 314
- United States v. Greene, 283
- United States v. Kylo, 301
- United States v. Slaughter, 296
- United States v. Wise, 293

Foreword

As you embark on this interdisciplinary and multidisciplinary study of Law and Biotechnology, my hope is that this book will assist you in examining the immense impact that biotechnology and law has on our society. It will undoubtedly affect you in your practice of law, in some way, during the course of your career; if not directly in many areas of practice which include not only intellectual property, but international trade, criminal law, agricultural law, business law and environmental law, to name but a few areas.

The practice of law is increasingly requiring a level of science literacy that will be required of anyone who is graduating from law school, today. This is particularly true in the field of biotechnology, which is a scientific field enjoying an explosion in growth and understanding, much like the scientific field of physics in the first half of the last century. As law develops to shape the way that our society regulates behaviors, it must quickly respond to the new and exciting possibilities of biotechnology. The opportunities to provide legal expertise and guidance in this field are great; and it is with an understanding of the science, scientists and engineers as well as the regulatory mechanisms that we can best optimize these opportunities for the benefit of society and future generations.

As this book goes to press, it is with the realization that new discoveries and new applications of the law in biotechnology will be developing as the ink is drying. But the foundations that are set forth in this text, provide you with the intellectual toolkit that should serve you well as you enter what will certainly be an exciting time in our history for judges, practicing lawyers and legal scholars in the field of Law and Biotechnology.

Victoria Sutton

Lubbock, TX

March 2007

Preface

This book provides a systematic look at law, policy, science and technology of biotechnology in the context of the traditional fields of law and practice. Chapter One begins with an introduction to the categories of biotechnologies as a way of understanding the scope of applications that are possible, raising awareness of law and policy issues. In this chapter, biotechnology is defined and the historical relationship between law and biotechnology is examined beginning with the earliest biotechnologies of food processing, animal breeding and winemaking and continuing up to the biotechnology explosion beginning in the 1980s. The chapter introduces the definitions for genomics, proteonomics, bionanotechnology and bioinformatics. An introduction to the scientific method and the sciences of biotechnology is explained at this early point in the book as a foundation to understanding. The chapter concludes by an introduction to the issue of whether life can be patented through examination of the case, *Diamond v. Chakrabarty*.

Chapter Two addresses issues of distributions of power in the regulation of biotechnology and a discussion of the earliest regulatory approaches in the development of the federal regulatory framework. The scope of authority for the regulation of biotechnology is examined through the litigation concerning genetically engineered foods with the Food and Drug Administration and Environmental Protection Agency, including administrative decisionmaking and Constitutional issues. The regulation of genetically modified organisms including plants and the environmental impact is examined through the litigation with the U.S. Environmental Protection Agency and Department of Agriculture and the National Institutes of Health. The work of biopharming is examined in the context of litigation with the U.S. Department of Agriculture. Completing this chapter is an examination of federal legislation which has been introduced concerning various policy issues of biotechnology, and the efforts of states to regulation biotechnology.

Chapter Three turns to the private sector and corporate activities in biotechnology, the unique features of biotechnology patents as well as the new professions which are developing around the emergence of biotechnologies in our lives. Unique problems for biotechnology of patent ownership, enforcement and infringement are examined in *Monsanto v. Schmeiser*.

Chapter Four, addresses some of the unique law and policy issues of biotechnology in human health, medical care and medical information. The constitutional right to privacy, adoption right to know, experimental and treatment decisions, informed consent and predisposition to disease as it relates to health insurance are among the ideas discussed in this chapter.

Chapter Five addresses international laws in biotechnology which affect the United States in the context of patenting, biological diversity, trade, security, biodefense, human rights, indigenous peoples, bioprospecting and biopiracy. Discussions of the

FAO International Treaty on Plant Genetic Resources for Food and Agriculture, the WTO Agreement on Trade-related Aspects of Intellectual Property Rights, the WIPO conventions and treaties, the International Convention for the Protection of New Varieties of Plants, the United Nations Convention on the Law of the Sea, the Convention on International Trade in Endangered Species of Wild Fauna and Flora, the Antarctic Treaty and the Human Genome Project are discussed in the context of biotechnologies.

Chapter Six tackles the broad area of ethics, religion and biotechnology by first examining religion and biotechnology and then ethics and biotechnology. Work of the National Bioethics Advisory Committee is reviewed as it explored the religious views of stem cell research and cloning among religious denominations. The family perspective is also reviewed from the question of who is family? Legal vs. biological definitions of family, reproductive technologies, eugenics, stem cell research and cloning are considered in this broad field of ethics, law and biotechnologies. The chapter concludes with consideration of the ethics of contamination of indigenous crops with genetically modified crops.

Chapter Seven considers criminal law and the role biotechnology has played in a range of legal contexts. Federal criminal statutes both new and old are explored in their application to biotechnologies. The use of DNA, and mitochondrial DNA in criminal law, the changing “expectation of privacy” with the use of new biotechnologies, human behavioral genetics and criminal predisposition are among the topics examined in this chapter. This is followed with cases which raise issues of ineffective representation by counsel where knowledge of biotechnology proves essential. A newly characterized crime of biopiracy is a final thought for the future in this chapter.

Chapter Eight reviews the foundation cases in scientific evidence and builds on these to introduce DNA testing and evidence. The emerging study of historical forensics examines some recent cases of interest to historians with legal consequences and raises new ethical issues for its practice.

Chapter Nine is introduced with the landmark case, of *Moore v. Regents of University of California* addressing the issue of ownership with human tissues. Special property protection problems of biotechnology are examined including the ownership of human organs, fertilized human eggs, sperm and umbilical cord blood storage banks.

Chapter Ten considers the application of traditional tort law to the new biotechnologies in the categories of intentional and unintentional torts, specifically trespass to land, conversion, private nuisance, public nuisance and negligence. Other torts are newly emerging areas which may utilize biotechnologies including wrongful birth and wrongful life, medical malpractice and products liability and strict liability.

The book necessarily concludes with a look at the future of law and biotechnology in the last Chapter Eleven.

Four appendices have been created specifically for the use of this book to assist in clarifying terms in biotechnology and general principles in the major scientific disciplines which are used to develop biotechnologies: cell biology, molecular biology, a primer on DNA and a glossary.

About the Author

Victoria Sutton, M.P.A., Ph.D., J.D.

Robert H. Professor of Law, Texas Tech University

Victoria Sutton is the Director of the Center for Biodefense, Law and Public Policy, Director of the Law and Science Certificate Program and the Robert H. Bean Professor of Law at Texas Tech University.

She holds a Ph.D. in Environmental Sciences from The University of Texas at Dallas; a J.D. from American University, *magna cum laude*; and a Master's Degree in Public Administration (MPA), from Old Dominion University, who awarded her the Distinguished Alumni Award in 2005. She also has two Bachelor of Science degrees in Zoology and Animal Science, *cum laude*, from North Carolina State University.

Before coming to Texas Tech, she was Assistant Director in the Bush Administration from 1990 to 1993, in the Office of Science and Technology Policy in the White House Science Office, where she worked on national energy and environmental policy. Prior to that, she worked in the U.S. Environmental Protection Agency as a Special Assistant in Policy, Planning and Evaluation and EPA Liaison to the Office of Science and Technology Policy of the White House. Following the Bush Administration, she was appointed as the Executive Director of the Ronald Reagan Institute of Emergency Medicine in Washington, DC.

Since coming to Texas Tech, Dr. Sutton was a Visiting Lecturer at Yale Law School in 2004 and also served in the President George W. Bush Administration as Chief Counsel of the Research and Innovative Technology Administration, U.S. Department of Transportation from 2005 to 2007.

Dr. Sutton is a member of the District of Columbia Bar, U.S. Federal Circuit Bar and the U.S. Supreme Court Bar. She has served as a consultant to a number of federal agencies in the area of biodefense, and is a frequent speaker for audiences of lawyers as well as scientists.

Her awards include receiving the Distinguished Alumni Award from Old Dominion University. She received the Texas Tech University Book Award in 2003 for *Law and Science: Cases and Materials*; and the Law School Distinguished Research Award in 2002, 2003 and 2005. She is also the author of *Law and Bioterrorism*, a first in the field, released January 2003.

Acknowledgments

First, I want to acknowledge Professor D. Allan Bromley, Sterling Professor of the Sciences, Yale University, for his tireless review of several drafts of the book and for sharing with me his incredible insight and knowledge of science, technology, science policy and life.

I would also like to thank the following contributors:

Anna McMinn for her research and explanations for Appendix 3. Primer on DNA.

Law students in my course, Law and Biotechnology, Texas Tech University School of Law, who used previous drafts of this book.

Chapter One

U.S. Department of Energy, Argonne National Laboratory, “Scientific Excellence,” *Frontiers* 2001 4–5 (2001).

These biotechnology descriptions are summarized from Helen Kreuzer, Ph.D. and Adrienne Massey, Ph.D., *Recombinant DNA and Biotechnology: A Guide for Teachers*, 2d ASM Press, Washington, D.C. (2001).

James Robert Dean, Jr, “FDA at War: Securing the Food That Secured Victory,” 53 Food Drug L.J. 453, 467–8 (1998).

U.S. Department of Energy’s Lawrence Livermore National Laboratory, “Research Highlights,” *Science and Technology Review*, 10–13 (January/February 2001).

“The Birth of Biotech: Herbert Boyer and Stanley Cohen started a revolution,” Association of Alumni and Alumnae of the Massachusetts Institute of Technology, *Technology Review* 120 (July/August 2000).

Chapter Two

Executive Office of the President, Federal Coordinating Council for Science, Engineering and Technology, “Biotechnology for the 21st Century,” (February 1992).

Stuart Auchincloss, “Does Genetic Engineering Need Genetic Engineers?: Should the Regulation of Genetic Engineering Include a New Professional Discipline?” 20 B.C. Env’tl. Aff. L. Rev. 37 (Fall 1993).

Jesse D. Lyon, “OPEN FORUM: Coordinated Food Systems and Accountability Mechanisms for Food Safety: A Law and Economics Approach,” 53 Food Drug L.J. 729 (1998) describes the history of law governing food.

Alliance for bio-Integrity website at <http://www.bio-integrity.org/list.html>.

Linda Beebe, “Symposium Issue II Pesticides: What Will the Future Reap? Note: In re Starlink Corn: The Link between Genetically Damaged Crops and an Inadequate Regulatory Frame Work for Biotechnology,” 28 Wm. & Mary Env’tl. L. & Pol’y Rev. 511 (Winter 2004).

Rebecca M. Bratspies, *Consuming (F)ears of Corn: Public Health and Biopharming*, 30 Am. J. L. and Med. 371 (2004).

Meredith A. Jagutis, "Comment: Insurer's Access to Genetic Information: The Call for Comprehensive Federal Legislation," 82 Marq. L.Rev. 429, 434–435 (Winter 1999).

11 Biotechnology Newswatch 11 (1991).

Kourtney L. Pickens, "Don't Judge Me By My Genes: A Survey of Federal Genetic Discrimination Legislation," 34 Tulsa L.J. 161, 170–172 (Fall 1998).

Natalie E. Zindorf, in "Comment: Discrimination in the 21st Century: Protecting the Privacy of Genetic Information in Employment and Insurance," 36 Tulsa L. J. 703, 714–715 (2001).

Chapter Three

Becca Alley, "The Biotechnology Process Patent Act of 1995: Providing Unresolved and Unrecognized Dilemmas in U.S. Patent Law," 12 J. Intell. Prop. L. 229 (Fall 2004).

Margaret M. Duncan, Kathleen Harris, Duncan Curley and Patrick D. Richards, McDermott, Will & Emery, "Legal Implications for Patenting Genomics and Proteomics" Proceedings of The Biotech Law & Litigation Summit, Palo Alto, California (April 30–May 1, 2001).

Beth Panitz, "Bioengineering: A Growing New Discipline," *PRISM American Society for Engineering Education* 22–24 (November 1996).

Jeri E. Reutenauer, "NOTE: Medical Malpractice Liability in the Era of Genetic Susceptibility Testing," 19 Quinnipiac L. Rev. 539 (2000).

Ernst and Young, LLP, Annual Biotechnology Industry Reports, 2000; Ernst and Young, *Beyond Borders*, 2002 and <http://www.bio.org/speeches/pubs/er/statistics.asp> are the sources of statistics for the biotechnology industry table in section 3.1.

Chapter Four

Renee C. Esfandiary, "NOTE: The Changing World of Genetics and Abortion: Why the Women's Movement Should Advocate for Limitations on the right to Choose in the Area of Genetic Technology," 4 Wm. & Mary J. Of Women & L. 499 (Spring 1998).

Jeri E. Reutenauer, "NOTE: Medical Malpractice Liability in the Era of Genetic Susceptibility Testing," 19 Quinnipiac L. Rev. 539 (2000).

Chapter Six

Winona LaDuke, "Wild Rice and Ethics," *Cultural Survival Quarterly Issue* 28.3 (September 15, 2004).

Gregg Zoroya, USA Today, February 12, 2007, Science makes a new father of a fallen American soldier: Banked sperm produces a son: 'He's a blessing'.

Jennifer S. Bard, "Immaculate Gestation? How Will Ectogenesis Change Current Paradigms of Social Relationships and Values?" Chap. Eleven, *Ecotogenesis: Artificial Womb Technology and the Future of Human Reproduction*, eds. Scott Gelfand and John R. Shook (2006) [excerpt].

Chapter Seven

Justin Gillis, "20 Years Later, Stolen Gene Haunts a Biotech Pioneer," Washington Post Staff Writer (Monday, May 17, 1999; Page A01).

Cecilee Price-Huish, “COMMENT: Born to Kill?” *Agression Genes* and Their Potential Impact on Sentencing and the Criminal Justice System,” 50 SMU L. Rev. 603 (Jan/Feb 1997).

Chapter Eight

Philip R. Reilly, *Abraham Lincoln’s DNA and Other Adventures in Genetics* 6–13 (Cold Spring Harbor Laboratory Press, 2000).

Chapter Nine

Sara Dastgheib-Vinarov, “COMMENT: A Higher Nonobviousness Standard for Gene Patents: Protecting Biomedical Research from the Big Chill,” Marq. Intell. Prop. L. Rev. 143 (2000).

Michael E. Sellers, “Patenting Nonnaturally Occurring, Man-Made Life: A Practical Look at the Economic, Environmental, and Ethical Challenges Facing Animal Patents,” 47 Ark. L. Rev. 269 (1994) New York Times, Blood Cord Banks.

Chapter Ten

Excerpt from Julie A. Davies and Lawrence C. Levine, “SYMPOSIUM: *Biotechnology and the Law: Biotechnology’s Challenge to the Law of Torts*,” 32 McGeorge L. Rev. 221 (Fall 2000).

Jeri E. Reutenauer, “NOTE: Medical Malpractice Liability in the Era of Genetic Susceptibility Testing,” 19 Quinnipiac L. Rev. 539 (2000).

Chapter Eleven

Henry Greely, “SPEECH: The Revolution in Human Genetics: Implications for Human Societies,” 52 S.C. L. Rev. 377 (Winter 2001).

Appendix 4. Glossary

This entire appendix is from “A Survey of the Use of Biotechnology in Industry,” (Dept. of Commerce, 2003) at: http://www.technology.gov/reports/Biotechnology/CD120a_0310.pdf.